KR20210114964A - 화농성 한선염 치료에 사용하기 위한 항-cd40 항체 - Google Patents

화농성 한선염 치료에 사용하기 위한 항-cd40 항체 Download PDF

Info

Publication number
KR20210114964A
KR20210114964A KR1020217024671A KR20217024671A KR20210114964A KR 20210114964 A KR20210114964 A KR 20210114964A KR 1020217024671 A KR1020217024671 A KR 1020217024671A KR 20217024671 A KR20217024671 A KR 20217024671A KR 20210114964 A KR20210114964 A KR 20210114964A
Authority
KR
South Korea
Prior art keywords
antibody
dose
seq
treatment
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217024671A
Other languages
English (en)
Korean (ko)
Inventor
파스칼 에스피에
크리스티안 뢰셰
루카스 로스
제임스 러쉬
그라지나 비에초레크
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210114964A publication Critical patent/KR20210114964A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217024671A 2019-01-11 2020-01-09 화농성 한선염 치료에 사용하기 위한 항-cd40 항체 Withdrawn KR20210114964A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19151461.1 2019-01-11
EP19151461 2019-01-11
PCT/IB2020/050132 WO2020144605A1 (en) 2019-01-11 2020-01-09 Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
KR20210114964A true KR20210114964A (ko) 2021-09-24

Family

ID=65019425

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024671A Withdrawn KR20210114964A (ko) 2019-01-11 2020-01-09 화농성 한선염 치료에 사용하기 위한 항-cd40 항체

Country Status (13)

Country Link
US (1) US12435150B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908310A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021506953A (cg-RX-API-DMAC7.html)
KR (1) KR20210114964A (cg-RX-API-DMAC7.html)
CN (1) CN113271964A (cg-RX-API-DMAC7.html)
AU (1) AU2020205839A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021013174A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125886A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001829A1 (cg-RX-API-DMAC7.html)
IL (1) IL284338A (cg-RX-API-DMAC7.html)
MX (1) MX2021008305A (cg-RX-API-DMAC7.html)
TW (1) TW202033558A (cg-RX-API-DMAC7.html)
WO (1) WO2020144605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061061A1 (en) * 2020-09-21 2022-03-24 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of inflammatory conditions
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
US20250304680A1 (en) * 2022-05-17 2025-10-02 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
TW202515607A (zh) * 2023-06-20 2025-04-16 英商凱麥博有限公司 Ox40及ox40l調節劑治療化膿性汗腺炎之用途
IL328258A (en) * 2024-01-03 2026-07-01 Abbvie Inc Luticizumab for use in the treatment of hidradenitis suppurativa
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation
WO2025235683A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2796467B1 (en) 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6518917B2 (ja) * 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗cd40抗体およびその使用
RU2020117156A (ru) * 2017-12-01 2022-01-04 Эббви Инк. Конъюгаты анти-cd40 антитела и лекарственного средства

Also Published As

Publication number Publication date
WO2020144605A1 (en) 2020-07-16
TW202033558A (zh) 2020-09-16
US20220098315A1 (en) 2022-03-31
EP3908310A1 (en) 2021-11-17
JP2021181439A (ja) 2021-11-25
BR112021013174A2 (pt) 2021-11-03
US12435150B2 (en) 2025-10-07
CA3125886A1 (en) 2020-07-16
AU2020205839A1 (en) 2021-06-03
CN113271964A (zh) 2021-08-17
MX2021008305A (es) 2021-08-24
JP2024178278A (ja) 2024-12-24
JP7558900B2 (ja) 2024-10-01
IL284338A (en) 2021-08-31
JP2021506953A (ja) 2021-02-22
CL2021001829A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
JP7558900B2 (ja) 化膿性汗腺炎の治療に使用するための抗cd40抗体
JP6900323B2 (ja) 抗ctla−4抗体およびその使用方法
US20250206833A1 (en) Anti-CD40 Antibodies for Use in Treatment of Sjogren's Syndrome
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗cd40抗体
IL293398B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JP2020536495A (ja) 抗lag−3抗体及びその使用
AU2015355150A1 (en) Methods for treating dry eye disease by administering an IL-6R antagonist
JP2022531698A (ja) 眼又は眼疾患を処置するための抗セマフォリン3a抗体及びその使用
RU2790558C2 (ru) Антитела к cd40 для применения в лечении синдрома шегрена
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
NZ727717B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202